Evidence map›Paper›PMID 34800368›Full record

ArticleImmunity2022

Type I interferon activates MHC class I-dressed CD11b

Ellen Duong, Tim B Fessenden, Emi Lutz, Teresa Dinter, Leon Yim, Sarah Blatt, Arjun Bhutkar, Karl Dane Wittrup, Stefani Spranger

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 239 papers.

0numbers the graph read from it
0cells of the map it votes in
239citing papers in PubMed
18.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

239 citing papers in PubMed, 334 citations in OpenAlex.

  1. Interferon regulatory factors orchestrate CD8International journal of molecular medicine · 2026
    Review
  2. Article
  3. Article
  4. Self-assembled supramolecular nanoparticles ofActa pharmaceutica Sinica. B · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Adaptive resistance in cancer immunotherapy.Cellular & molecular immunology · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

179 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ellen DuongKoch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA; Department of Biology, MIT, Cambridge, MA, USA.
Tim B FessendenKoch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA.
Emi LutzKoch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA; Department of Biological Engineering, MIT, Cambridge, MA, USA.
Teresa DinterKoch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA; Department of Biology, MIT, Cambridge, MA, USA.
Leon YimKoch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA.
Sarah BlattKoch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA.
Arjun BhutkarKoch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA.
Karl Dane WittrupKoch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA; Department of Biological Engineering, MIT, Cambridge, MA, USA.
Stefani SprangerKoch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA; Department of Biology, MIT, Cambridge, MA, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. Electronic address: spranger@mit.edu.
Allen Institute · USIIT@MIT · USRagon Institute of MGH, MIT and Harvard · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond · 1985 to 2026
$93.9M
PRE-DOCTORAL TRAINING IN THE BIOLOGICAL SCIENCEST32GM007287 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELL, STEPHEN P., KEATING, AMY E · 1985 to 2019
$40.8M
Tumor-intrinsic oncogenic alterations and evasion of anti-tumor immunityR00CA204595 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SPRANGER, STEFANI · 2017 to 2019
$747k
NCI NIH HHS P30 CA014051NCI NIH HHS R00 CA204595NIGMS NIH HHS T32 GM007287
6 · The paper itself

Abstract

Tumor-infiltrating dendritic cells (DCs) assume varied functional states that impact anti-tumor immunity. To delineate the DC states associated with productive anti-tumor T cell immunity, we compared spontaneously regressing and progressing tumors. Tumor-reactive CD8

Indexed as

AnimalsAntigens, NeoplasmCD11b AntigenCD8-Positive T-LymphocytesCross-PrimingDendritic CellsHistocompatibility Antigens Class IInterferon-betaInterferon Type ILymphocytes, Tumor-InfiltratingMiceNeoplasmsReceptors, InterferonSignal TransductionTumor MicroenvironmentAntigens, NeoplasmCD11b AntigenHistocompatibility Antigens Class IInterferon-betaInterferon Type IItgam protein, mouseReceptors, Interferonanti-tumor immunitycross-presentationdendritic cellsimmunotherapyMHC class I dressingoptimal anti-tumor immunityT cell exhaustiontumor regressiontype 2 dendritic cellstype I interferon

Identifiers

PMID34800368
PMCPMC10827482
OpenAlexW3216766978

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.